Advertisement

Clinical Drug Investigation

, Volume 15, Issue 2, pp 111–121 | Cite as

Effect of Aldose Reductase Inhibition on Heart Rate Variability in Patients with Severe or Moderate Diabetic Autonomic Neuropathy

  • Triantaffilos P. Didangelos
  • Vasilios G. Athyros
  • Dimitrios T. Karamitsos
  • Athanasios A. Papageorgiou
  • Georgios I. Kourtoglou
  • Athanasios G. Kontopoulos
Clinical Pharmacodynamic

Summary

Patients with diabetic autonomic neuropathy (DAN) have an increased cardiovascular mortality rate compared with diabetic patients without DAN. Heart rate variability (HRV) time and frequency domain indices are strong predictors of malignant arrhythmias and sudden cardiac death. This prospective, randomised, double-blind, placebo-controlled study analysed the long-term effect of an aldose reductase inhibitor, tolrestat, on HRV time and frequency domain variables in 45 patients with diabetes mellitus (DM) and DAN. Patients were randomised into tolrestat (n = 22) and placebo (n = 23) groups. Tolrestat (200 mg/day) or placebo were administered, respectively, for a period of 12 months. HRV was assessed at months 0, 3, 6, 9 and 12. The HRV level of the 45 patients was compared with that of 20 patients with DM, with analogous glycaemic control, without DAN and 20 healthy controls, of similar age and gender. At the twelfth month, tolrestat, compared with placebo, had a beneficial effect on HRV indices related to vagal tone. Compared with baseline, HRV time and frequency domain indices showed no significant improvement. Moreover, at the twelfth month of tolrestat administration, HRV indices remained less than that of patients with DM but without DAN, and healthy controls. The 12 patients of the 22 with moderate DAN benefited more than the 10 patients of the 22 with severe DAN. At the twelfth month no patient showed deterioration in HRV indices with tolrestat as was seen with placebo. Our data suggest that tolrestat slows down the progression of DAN compared with placebo. This effect of an aldose reductase inhibitor may contribute to a reduction in risk for malignant ventricular arrhythmias. The early detection of DAN is imperative for successful intervention.

Keywords

Adis International Limited Heart Rate Variability Drug Invest High Frequency Power Aldose Reductase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Task Force of the European Society of Cardiology and the North American Society of Pacing and Electophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996; 17: 354–81CrossRefGoogle Scholar
  2. 2.
    van Ravenswaaij CMA, Kollee LAA, Hopman JCW, et al. Heart rate variability. Ann Intern Med 1993; 118: 436–47Google Scholar
  3. 3.
    Genis AB, Guidino J, Vinolas X, et al. Autonomic influences of ventricular arrhythmias: Experimental and clinical aspects. In: Diez J, Dzau VJ, Ferrari R, et al., editors. Molecular cell biology of cardiovascular diseases. Madrid: Mosby/Doyma Libros, 1995: 255–9Google Scholar
  4. 4.
    Regani M, Malfatto G, Pierini S, et al. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. J Auton Nerv Syst 1988; 23: 143–53CrossRefGoogle Scholar
  5. 5.
    Ewing DJ, Campbell IW, Clarke BE. The natural history of diabetic autonomic neuropathy. Q J Med 1980; 193: 95–108Google Scholar
  6. 6.
    Sampson MJ, Wilson S, Karagiannis P, et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 1990; 278: 635–46Google Scholar
  7. 7.
    O'Brien IA, McFadden JP, Corrall RJM. The influence of diabetic autonomic neuropathy on mortality in insulin-dependent diabetics. Q J Med 1991; 290: 495–502Google Scholar
  8. 8.
    Broomgarden ZT. Neuropathy and retinopathy. American Diabetes Association Scientific Sessions, 1995. Diabetes Care 1995; 18: 1314–7Google Scholar
  9. 9.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561–8Google Scholar
  10. 10.
    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRefGoogle Scholar
  11. 11.
    Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995; 11: 193–225PubMedCrossRefGoogle Scholar
  12. 12.
    The American Diabetes Association and the American Academy of Neurology. Consensus Statement. Standardized measures in diabetic neuropathy. Diabetes Care 1995; 18(1 Suppl.): 59S–82SGoogle Scholar
  13. 13.
    Genovely H, Pfeifer MA. RR-variation: the autonomic test of choice in diabetes. Diabetes Metab Rev 1988; 3: 255–71CrossRefGoogle Scholar
  14. 14.
    Boudoulas H, Mantzouratos D, Sohn YH, et al. Left ventricular mass and systolic performance in chronic systemic hypertension. Am J Cardiol 1988; 57: 232–7CrossRefGoogle Scholar
  15. 15.
    Kontopoulos A, Athyros V, Papageorgiou A, et al. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am J Cardiol 1996; 77: 242–6PubMedCrossRefGoogle Scholar
  16. 16.
    Jungsblut M. Erfassung and analyse der herzfrequenz-variabilitat auf basis des Langzeit-EKG-Systems. Thesis, Hamburg, Germany, 1993Google Scholar
  17. 17.
    Lombardi F, Sandrone G, Pernpruner S, et al. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol 1987; 60: 1239–45PubMedCrossRefGoogle Scholar
  18. 18.
    Spallone V, Uccioli L, Menzinger G. Diabetic autonomic neuropathy. Diabetes Metab Rev 1995; 11: 227–57PubMedCrossRefGoogle Scholar
  19. 19.
    Fagius J, Brattberg A, Jameson S, et al. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323–9PubMedCrossRefGoogle Scholar
  20. 20.
    Green A, Jaspan J, Kavin H, et al. Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients. Diabetes Res Clin Pract 1987; 4: 67–75PubMedCrossRefGoogle Scholar
  21. 21.
    Pitts NE, Vreeland F, Shaw GL, et al. Clinical experience with sorbinil — an aldose reductase inhibitor. Metabolism 1986; 35(4 Suppl. 1): 96S–100SCrossRefGoogle Scholar
  22. 22.
    Sundkvist G, Armstrong FM, Bradbury JE, et al. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J Diabetes Complications 1992; 6: 123–30PubMedCrossRefGoogle Scholar
  23. 23.
    Gill JS, Williams G, Ghatei MA, et al. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabéte Métab 1990; 16: 296–302PubMedGoogle Scholar
  24. 24.
    Ziegler D, Mayer P, Rathman W, et al. One-year treatment with aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 1991; 14: 63–74PubMedCrossRefGoogle Scholar
  25. 25.
    Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536–41PubMedCrossRefGoogle Scholar
  26. 26.
    Giugliano D, Marfella R, Quatraro A, et al. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993; 118: 7–11PubMedGoogle Scholar
  27. 27.
    Ziegler D. Diabetic cardiovascular neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994; 10: 339–83PubMedCrossRefGoogle Scholar
  28. 28.
    Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20: 355–61PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Triantaffilos P. Didangelos
    • 1
  • Vasilios G. Athyros
    • 2
  • Dimitrios T. Karamitsos
    • 1
  • Athanasios A. Papageorgiou
    • 3
  • Georgios I. Kourtoglou
    • 1
  • Athanasios G. Kontopoulos
    • 2
  1. 1.Division of DiabetologyAristotelian University, Hippocration HospitalThessalonikiGreece
  2. 2.Division of CardiologyAristotelian University, Hippocration HospitalThessalonikiGreece
  3. 3.2nd Propedeutic Department of Internal MedicineAristotelian University, Hippocration HospitalThessalonikiGreece

Personalised recommendations